+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID04068649

Phase 2 Study Comparing Single-Fraction Stereotactic Body Radiation Therapy SBRT to Standard Palliative Radiation in Adults with Metastatic Cancer

Led by Roswell Park Cancer Institute · Updated on 2026-04-30

1500

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how well single-fraction stereotactic body radiation therapy SBRT works compared to standard palliative radiation therapy in patients with metastatic cancer, where the disease has spread to other parts of the body. This phase II study aims to assess patient-reported pain response and quality of life, as well as overall survival, immune marker changes, radiation toxicity, frailty, cognitive function, circadian rhythm effects, and the Pain Catastrophizing Index in this patient population. Participants are randomly assigned to one of two treatment groups. One group receives standard palliative radiation therapy, with 1, 3-5, 5-6, or 10 fractions as determined appropriate by the treating physician. The other group receives a single fraction of SBRT, which uses specialized equipment to deliver highly precise radiation doses to tumors, potentially reducing treatment time and minimizing damage to healthy tissue. After the treatment, patients may have follow-up visits at 5 and 12 weeks. During the study, patients complete surveys and clinical assessments before and after treatment to track pain levels and changes in quality of life up to 12 weeks. Researchers also monitor overall survival and examine other health markers such as immune system changes, frailty, cognitive function, and treatment-related side effects. Participation involves completing questionnaires and clinical evaluations to help measure the effects of the different radiation therapies on symptoms and wellbeing.

CONDITIONS

Brief Title

Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here